Zynex Future Growth

Future criteria checks 1/6

Zynex is forecast to grow earnings and revenue by 36.5% and 11.3% per annum respectively while EPS is expected to grow by 38.7% per annum.

Key information

36.5%

Earnings growth rate

38.75%

EPS growth rate

Medical Equipment earnings growth	12.7%
Revenue growth rate	11.3%
Future return on equity	n/a
Analyst coverage	Low
Last updated	30 Apr 2025

Recent future growth updates

Recent updates

Here's Why It's Unlikely That Zynex, Inc.'s (NASDAQ:ZYXI) CEO Will See A Pay Rise This Year

May 09

Capital Allocation Trends At Zynex (NASDAQ:ZYXI) Aren't Ideal

Apr 24

More Unpleasant Surprises Could Be In Store For Zynex, Inc.'s (NASDAQ:ZYXI) Shares After Tumbling 66%

Mar 21

Calculated Diversification And Sales Optimization Set To Propel Long-Term Growth And Profitability

Sep 26 Enhancing future growth and stability through diversification of product lines and refining sales force efficiency, emphasizing long-term revenue and profitability.

With Zynex, Inc. (NASDAQ:ZYXI) It Looks Like You'll Get What You Pay For

Jul 31

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

May 03

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Mar 03

Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E

Jan 24

Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?

Aug 03

Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Mar 30

Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?

Jan 23

Earnings and Revenue Growth Forecasts

NasdaqGS:ZYXI - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	180	0	N/A	N/A	2
12/31/2026	139	-13	N/A	5	3
12/31/2025	117	-24	N/A	-15	3
3/31/2025	172	-7	0	0	N/A
12/31/2024	192	3	12	13	N/A
9/30/2024	194	5	16	16	N/A
6/30/2024	194	6	17	18	N/A
3/31/2024	189	8	17	18	N/A
12/31/2023	184	10	17	18	N/A
9/30/2023	186	16	16	16	N/A
6/30/2023	177	17	14	15	N/A
3/31/2023	169	17	13	14	N/A
12/31/2022	158	17	13	14	N/A
9/30/2022	150	18	16	17	N/A
6/30/2022	143	20	12	13	N/A
3/31/2022	137	19	14	14	N/A
12/31/2021	130	17	6	7	N/A
9/30/2021	116	10	-3	-2	N/A
6/30/2021	101	5	-7	-7	N/A
3/31/2021	89	5	-6	-5	N/A
12/31/2020	80	9	0	1	N/A
9/30/2020	69	10	4	5	N/A
6/30/2020	60	11	7	7	N/A
3/31/2020	52	10	5	5	N/A
12/31/2019	45	9	6	6	N/A
9/30/2019	41	9	7	7	N/A
6/30/2019	37	10	8	8	N/A
3/31/2019	34	10	9	10	N/A
12/31/2018	32	10	N/A	9	N/A
9/30/2018	31	10	N/A	10	N/A
6/30/2018	29	10	N/A	10	N/A
3/31/2018	27	9	N/A	9	N/A
12/31/2017	23	7	N/A	8	N/A
9/30/2017	18	4	N/A	5	N/A
6/30/2017	15	3	N/A	3	N/A
3/31/2017	13	1	N/A	1	N/A
12/31/2016	13	0	N/A	2	N/A
9/30/2016	13	-1	N/A	1	N/A
6/30/2016	12	-2	N/A	1	N/A
3/31/2016	12	-2	N/A	1	N/A
12/31/2015	12	-3	N/A	0	N/A
9/30/2015	11	-1	N/A	0	N/A
6/30/2015	13	-1	N/A	0	N/A
3/31/2015	11	-6	N/A	1	N/A
12/31/2014	11	-6	N/A	1	N/A
9/30/2014	12	-11	N/A	1	N/A
6/30/2014	13	-12	N/A	1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZYXI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ZYXI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ZYXI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ZYXI's revenue (11.3% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: ZYXI's revenue (11.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ZYXI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/12 00:10
End of Day Share Price	2025/05/12 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zynex, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Marc Wiesenberger	B. Riley Securities, Inc.
Parth Talsania	Equisights
Yi Chen	H.C. Wainwright & Co.

Zynex Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Consensus revenue estimates fall by 16%

Price target decreased by 37% to US$6.50

Zynex Inc. Provides Earnings Guidance for Second Quarter of 2025

Consensus revenue estimates fall by 42%

Zynex Inc. Provides Earnings Guidance for First Quarter of 2025

Zynex, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Recent updates

Zynex, Inc. Submits FDA Application for its NiCO Laser Pulse Oximeter

Here's Why It's Unlikely That Zynex, Inc.'s (NASDAQ:ZYXI) CEO Will See A Pay Rise This Year

Consensus revenue estimates fall by 16%

Price target decreased by 37% to US$6.50

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Zynex Inc. Provides Earnings Guidance for Second Quarter of 2025

Investor sentiment improves as stock rises 16%

Capital Allocation Trends At Zynex (NASDAQ:ZYXI) Aren't Ideal

Zynex, Inc. to Report Q1, 2025 Results on Apr 29, 2025

Zynex, Inc., Annual General Meeting, May 15, 2025

Zynex, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

More Unpleasant Surprises Could Be In Store For Zynex, Inc.'s (NASDAQ:ZYXI) Shares After Tumbling 66%

Investor sentiment deteriorates as stock falls 21%

Consensus revenue estimates fall by 42%

New minor risk - Market cap size

Now 52% undervalued after recent price drop

Zynex Inc. Provides Earnings Guidance for First Quarter of 2025

Zynex, Inc. to Report Q4, 2024 Results on Mar 11, 2025

Chief Financial Officer notifies of intention to sell stock

Zynex UCSF Study Results Demonstrate Laser Technology Benefits in Resolving Racial Bias of Current LED Pulse Oximeters

Zynex, Inc. Announces Completion of Its Laser Pulse Oximetry Trial

Zynex's (NASDAQ:ZYXI) Returns On Capital Not Reflecting Well On The Business

Investor sentiment improves as stock rises 16%

Founder notifies of intention to sell stock

Now 21% undervalued

Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Zynex, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Zynex, Inc. to Report Q3, 2024 Results on Oct 24, 2024

Zynex, Inc.: 2025 Looks Like A Brighter Year

Calculated Diversification And Sales Optimization Set To Propel Long-Term Growth And Profitability

Zynex, Inc. Obtains FDA Clearance for New Pain Management Device

Chief Operating Officer recently sold US$199k worth of stock

Investor sentiment deteriorates as stock falls 18%

Chief Financial Officer recently sold US$124k worth of stock

Consensus revenue estimates decrease by 11%

With Zynex, Inc. (NASDAQ:ZYXI) It Looks Like You'll Get What You Pay For

Price target decreased by 17% to US$17.50

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Zynex, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024

Zynex, Inc. to Report Q2, 2024 Results on Jul 25, 2024

Zynex, Inc.(NasdaqGS:ZYXI) dropped from Russell 2000 Growth-Defensive Index

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

Zynex, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Reaffirms for the Full Year 2024

Price target increased by 8.1% to US$19.88

First quarter 2024 earnings released: EPS: US$0 (vs US$0.043 in 1Q 2023)

Zynex, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Zynex, Inc., Annual General Meeting, May 16, 2024

Consensus EPS estimates fall by 11%

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zynex, Inc. Provides Earnings Guidance First Quarter and Full Year 2024

Zynex, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Zynex, Inc. Introduces New Products

Zynex, Inc. Receives FDA Clearance for its Next Generation NMES Device

Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E

Zynex, Inc. Submits FDA Application for Its NMES Device

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $20 million worth of its shares.

Zynex, Inc. Provides Earnings Guidance for Fourth Quarter and Full Year of 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 24% to US$16.50

Investor sentiment deteriorates as stock falls 15%

Zynex, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Now 23% undervalued after recent price drop

Now 22% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Now 23% undervalued after recent price drop

Chief Financial Officer recently sold US$170k worth of stock